• Blog
  • Sickle Cell Market Report

    Sickle Cell Market Report

    Sickle Cell Market Report
    Report code - SRHL328 Delivery - 2 Weeks
    Sickle Cell Market, Dynamics, Trends, and Market Analysis - 2023-2028
    See more...

    Market Insights

    The global sickle cell market size was estimated at USD 3.23 billion in 2023 and is likely to grow at a CAGR of 14.40% during 2023-2028 to reach USD 6.33 billion in 2028.

    sickle-cell-market-size

    Wish to get a free sample on this study? Click here.

    What is sickle cell?

    Sickle cell anemia is defined as an inherited red blood cell disorder in which the number of healthy red blood cells that carry oxygen throughout the body is not sufficient. The red blood cells are shaped like sickles or crescent moons in the person having sickle cell disease. These cells can get stuck in the small blood vessels and thus, slow or block blood flow and oxygen.

    COVID-19 Impact

    The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the sickle cell market negatively as patients postponed their appointments due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the market growth further.

    Sickle Cell Market Report Overview

    Market Size in 2028

    USD 6.33 Billion

    Market Size in 2023

    USD 3.23 Billion

    Market Growth (2023-2028)

    CAGR of 14.40%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Key Players

    Key players operating in the global sickle cell market are-

    • Bluebird bio, Inc. (The U.S),
    • Eli Lilly and Company (The U.S),
    • Gilead Sciences, Inc. (The U.S),
    • Merck & Co., Inc. (The U.S),
    • Novartis International AG (Switzerland),
    • Sanofi S.A. (France),
    • Baxter International Inc. (The U.S),
    • Bristol-Myers Squibb  (The U.S),
    • Global Blood Therapeutics (The U.S),
    • Johnson & Johnson (The U.S),
    • Mast Therapeutics (The U.S), and
    • Pfizer, Inc. (The U.S).

    Market Dynamics

    The global market growth is primarily driven by the increasing prevalence of sickle cell traits among patients.

    • The market players are continuously emphasizing on development of technologically advanced solutions to treat the disease and reduce the mortality rate of patients suffering from sickle cell disease.
    • Increasing clinical trials using various therapies is likely to create lucrative opportunities for the players operating in the global market. However, the high treatment cost is likely to pose a hindrance to the market growth.

    Segment Analysis

    End User Trends

    Based on end user, the market has been divided into hospital, clinic and home healthcare.

    • The hospitals segment accounted for the largest market share of more than 30% in 2022.
    • The segment growth can be attributed to increasing number of people suffering from sickle disease in the hospitals.
    • The clinic segment is projected to register highest growth during the review period.

    Regional Trends

    The market in North America accounted for the largest share in 2022 and is projected to register significant growth during the review period.

    • The regional market growth can be attributed to the availability of required infrastructure and technologies to treat the patients having the sickle disease.
    • The market in the Asia-Pacific region is projected to register the fastest growth rate on account of rising consumer awareness and advancement in healthcare infrastructure in developing countries.

    Critical Questions answered in this report-

    • What are the key trends in the global Sickle Cell market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Sickle Cell market?
    • What are the key strategies adopted by the major vendors to lead in the global Sickle Cell market?
    • What is the market share of the top vendors?

    sickle-cell-market-regional-insights

    Wish to know more about the study? Click here.

    Target Audience

    • Sickle cell distributors
    • Sickle cell suppliers
    • Sickle cell manufacturers
    • Logistics organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Bluebird bio, Inc. (The U.S), Eli Lilly and Company (The U.S), Gilead Sciences, Inc. (The U.S), Merck & Co., Inc. (The U.S), Novartis International AG (Switzerland), Sanofi S.A. (France), Baxter International Inc. (The U.S), Bristol-Myers Squibb (The U.S), Global Blood Therapeutics (The U.S), Johnson & Johnson (The U.S), Mast Therapeutics (The U.S) and Pfizer, Inc. (The U.S) are among the key players in the market.

    North America accounted for the largest share in 2022 and is projected to register significant growth.

    Asia-pacific is expected to register the fastest growth rate in the sickle cell market in the coming years.

    The clinic segment is expected to register the highest growth in the market during the review period.

    Increasing prevalence of sickle cell traits among patients, increasing clinical trials using various therapies are the factors driving the growth of sickle cell market.

    Sickle cell distributors, Sickle cell suppliers, Sickle cell manufacturers, Logistics organizations, Government bodies are the target audience in the market.